High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis

Trendelenburg, Marten; López‐Trascasa, Margarita; Potluková, Eliška; Moll, Solange; Regenass, Stephan; Frémeaux‐Bacchi, Véronique; Martínez-Ara, Jorge; Jančová, Eva; Picazo, Mari Luz; Honsová, Eva; Tesař, Vladimı́r; Sadallah, Salima; Schifferli, Jürg A.

doi:10.1093/ndt/gfl436

Cited by 163 publications

(153 citation statements)

References 24 publications

Supporting

Mentioning

137

Contrasting

Unclassified

Order By: Relevance

“…Therefore, the absence of anti-C1q antibodies has been suggested as an indicator for excluding a diagnosis of lupus nephritis [Trendelenburg et al 1999[Trendelenburg et al , 2006. Significant correlations between anti-C1q titers and active lupus nephritis have also been reported [Akhter et al 2011;Moroni et al 2001;Trendelenburg et al 2006], with a sensitivity of 44-100% and a specificity of 70-92% reported by Moroni and colleagues [Moroni et al 2001]. Another study reported the detection of anti-C1q antibodies in SLE patients who did not have a history of renal disease but eventually developed lupus nephritis [Marto et al 2005].…”

Section: Antinucleosome Antibodiesmentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers in systemic lupus erythematosus: challenges and prospects for the future

Liu

Kao

Manzi

et al. 2013

Therapeutic Advances in Musculoskeletal

106

View full text Add to dashboard Cite

Abstract:The search for lupus biomarkers to diagnose, monitor, stratify, and predict individual response to therapy is currently more intense than ever before. This effort is essential for several reasons. First, epidemic overdiagnosis and underdiagnosis of lupus, even by certified rheumatologists, leads to errors in therapy with concomitant side effects which may be more serious than the disease itself. Second, identification of lupus flares remains as much an art as it is a science. Third, the capacity to stratify patients so as to predict those who will develop specific patterns of organ involvement is not currently possible but would potentially lead to preventive therapeutic strategies. Fourth, only one new drug for the treatment of lupus has been approved by the US Food and Drug Administration in over 50 years. A major obstacle in this pipeline is the dearth of biomarkers available to prove a patient has responded to an experimental therapeutic intervention. This review will summarize the challenges faced in the discovery and validation of lupus biomarkers, the most promising lupus biomarkers identified to date, and the promise of future directions.

show abstract

Section: Antinucleosome Antibodiesmentioning

confidence: 99%

“…Some investigators suggested that the prediction value would be further enhanced when both anti-C1q and anti-dsDNA were measured [Matrat et al 2011]. Moreover, it has been reported that levels of anti-C1q antibodies decreased after successful treatment of lupus nephritis [Trendelenburg et al 2006].…”

Section: Antinucleosome Antibodiesmentioning

confidence: 99%

Biomarkers in systemic lupus erythematosus: challenges and prospects for the future

Liu

Kao

Manzi

et al. 2013

Therapeutic Advances in Musculoskeletal

106

View full text Add to dashboard Cite

show abstract

“…9 Other biomarkers may reflect specific organ involvements, most notably lupus nephritis which is often mirrored by raised levels of autoantibodies against double-stranded (ds) DNA, nucleosomes and/or complement protein (C) 1q. 2,5,10 The Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index (SDI) 11 covers 12 organ systems and measures accumulated organ damage that has occurred since the onset of SLE. SDI is scored regardless of whether the damage can be attributed to SLE or to other causes.…”

Section: Introductionmentioning

confidence: 99%

Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus

Enocsson

Wetterö

Skogh

et al. 2013

Translational Research

View full text Add to dashboard Cite

Compared to healthy controls, serum suPAR levels were significantly elevated in SLE patients. No association was recorded regarding suPAR levels and SLE disease activity in cross-sectional or consecutive samples. However, a strong association was observed between suPAR and SDI (p<0.0005). Considering distinct SDI domains, renal, neuropsychiatric, ocular, skin and peripheral vascular damage had significant impact on suPAR levels.This study is the first to demonstrate an association between serum suPAR and irreversible organ damage in SLE. Further studies are warranted to evaluate suPAR and other biomarkers as predictors of evolving organ damage.

show abstract

“…Soluble VCAM-1 (sVCAM-1) has been reported as a useful marker of adult SLE activity [9,10]. On the other hand, deficiency of the early classical pathway component C1q induces tissue damage [11,12] and the occurrence of autoantibodies to C1q in SLE has been shown to be associated with hypocomplementemia and severe active LN [13][14][15].…”

Section: Introductionmentioning

confidence: 99%

Markers of childhood lupus nephritis indicating disease activity

et al. 2010

View full text Add to dashboard Cite

Current treatment regimens for childhood lupus nephritis (LN) are associated with significant side-effects and toxicity in vulnerable phases of growth and development. The paucity of biomarkers particularly in childhood impedes the appropriate clinical management and the development of new therapeutics. We analyzed markers of immune system (BAFF, RANTES), complement (Bb, C1q, C3d-CIC, C5a) and endothelial cell activation (sVCAM-1) in children with LN (n=22, mean age 14.8±4.7 years), nephrotic syndrome (n =13) and age-matched healthy controls (n=20) to define parameters that correlate with LN activity. Complement fragments of the alternative (Bb, p=0.0004) classical (C3d-CIC, p<0.0001) and common pathway (C5a, p<0.0001) and the levels of BAFF (p< 0.0001), RANTES (p=0.0002) and sVCAM-1 (p=0.0004) were significantly higher in active compared to inactive LN. Activation of complement was associated with the occurrence of anti-C1q antibodies and reduced complement

show abstract

High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis

Abstract: Anti-C1q have a very high prevalence in biopsy-proven active lupus nephritis, thus a negative test result almost excludes active nephritis. The data support the hypothesis of a pathogenic role of anti-C1q in lupus nephritis.

Cited by 163 publications

References 24 publications

Biomarkers in systemic lupus erythematosus: challenges and prospects for the future

Biomarkers in systemic lupus erythematosus: challenges and prospects for the future

Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus

Markers of childhood lupus nephritis indicating disease activity

Contact Info

Product

Resources

About